3-(4-phenyl-1H-imidazol-1-yl)propionaldehyde | 166947-15-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(4-phenyl-1H-imidazol-1-yl)propionaldehyde
• 英文别名: 3-(4-phenyl-1H-imidazole-1-yl)-propanal；3-(4-phenyl-imidazol-1-yl)-propioaldehyde；3-(4-phenylimidazol-1-yl)propanal
• CAS: 166947-15-5
• 化学式: C₁₂H₁₂N₂O
• 分子量: 200.24
• InChiKey: UXFKFJVEGHQOGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(4-phenyl-1H-imidazol-1-yl)propionaldehyde 、 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 生成 2,3-anhydro-5-O-desosaminyl-11-{[3-(4-phenylimidazolyl)propyl]hydrazo}-6-O-methylerythronolide A, 11,12-carbamate
  参考文献：
  名称：

  Anhydrolide Macrolides. 2. Synthesis and Antibacterial Activity of 2,3-Anhydro-6-O-methyl 11,12-Carbazate Erythromycin A Analogues

  摘要：

  A series of 3-descladinosyl-2,3-anhydro-6-O-methylerythromycin A 11,12-cyclic carbazate analogues was prepared and evaluated for antibacterial activity. These 2,3-anhydro macrolides were found to be potent antibacterial agents in vitro against macrolide-susceptible organisms including Staphylococcus aureus 6538P, Streptococcus pyogenes EES61, and Streptococcus pneumoniae ATCC6303. These compounds were also very active against some organisms that show macrolide resistance (S. aureus A5177, S. pyogenes PIU2584, and S. pneumoniae 5649). The compounds generally showed poor activity against organisms with constitutive MLS resistance. Selected compounds were evaluated in vivo in mouse protection studies. Although most of the compounds tested in vivo showed poor efficacy, two compounds, 38 and 57, were more active than clarithromycin against S. pneumoniae ATCC6303.

  DOI：

  10.1021/jm970548p
• 作为产物：
  描述：

  4-苯基咪唑 在 盐酸 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 124.0h， 生成 3-(4-phenyl-1H-imidazol-1-yl)propionaldehyde
  参考文献：
  名称：

  Anhydrolide Macrolides. 2. Synthesis and Antibacterial Activity of 2,3-Anhydro-6-O-methyl 11,12-Carbazate Erythromycin A Analogues

  摘要：

  A series of 3-descladinosyl-2,3-anhydro-6-O-methylerythromycin A 11,12-cyclic carbazate analogues was prepared and evaluated for antibacterial activity. These 2,3-anhydro macrolides were found to be potent antibacterial agents in vitro against macrolide-susceptible organisms including Staphylococcus aureus 6538P, Streptococcus pyogenes EES61, and Streptococcus pneumoniae ATCC6303. These compounds were also very active against some organisms that show macrolide resistance (S. aureus A5177, S. pyogenes PIU2584, and S. pneumoniae 5649). The compounds generally showed poor activity against organisms with constitutive MLS resistance. Selected compounds were evaluated in vivo in mouse protection studies. Although most of the compounds tested in vivo showed poor efficacy, two compounds, 38 and 57, were more active than clarithromycin against S. pneumoniae ATCC6303.

  DOI：

  10.1021/jm970548p

文献信息

• KETOLIDE DERIVATIVES AS ANTIBACTERIAL AGENTS
  申请人：Das Biswajit

  公开号：US20090170790A1

  公开（公告）日：2009-07-02

  The present invention provides ketolide derivatives, which can be used as anti-bacterial agents. Compounds disclosed herein can be used for the treating or preventing conditions caused by or contributed to by gram positive, gram negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp., Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus , Enterobactericeae or any combination thereof. Also provided are processes for preparing compounds disclosed herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods of treating bacterial infections.

  本发明提供了酮烯类衍生物，可用作抗菌剂。本文披露的化合物可用于治疗或预防由革兰氏阳性、革兰氏阴性或厌氧细菌引起或导致的疾病，更具体地针对例如葡萄球菌、链球菌、肠球菌、流感嗜血杆菌、嗜痰菌属、衣原体属、支原体、军团菌属、分枝杆菌、幽门螺杆菌、梭菌、拟杆菌、白色杆菌、杆菌、肠杆菌科细菌或其任意组合。还提供了制备本文披露的化合物的方法、用于合成的中间体、其制药组合物以及治疗细菌感染的方法。
• Trisubstituted benzene derivatives, composition and methods of treatment
  申请人：Eisai Co., Ltd.

  公开号：US05668136A1

  公开（公告）日：1997-09-16

  A benzene, pyridine or pyrimidine derivative having the below shown formula is novel and useful as an anti-arteriosclerotic agent. ##STR1## wherein R.sup.1 stands for a lower alkyl group, an amino group which may be substituted, or the like; R.sup.2 stands for a group represented by the formula: ##STR2## (wherein R.sup.16 stands for an alkyl group having 1 to 6 carbon atoms, or the like) or the like; R.sup.3 stands for a group represented by the formula: --O--(CH.sub.2).sub.m --Y (Y stands for an imidazolyl or piperazinyl group, or the like and m is 1 to 6) or the like; R.sup.5 stands for a hydrogen atom, a lower alkyl group, or the like; A stands for a group represented by the formula: ##STR3## (wherein R.sup.6 stands for a hydrogen atom, a lower alkyl group, or the like), --N.dbd., or the like; and B stands for a group represented by the formula: ##STR4## (wherein R.sup.4 stands for a hydrogen or the like), --N.dbd., or the like.

  苯、吡啶或嘧啶衍生物具有以下所示的化学式，作为一种抗动脉粥样硬化药物是新颖和有用的。其中R.sup.1代表低碳烷基、可能被取代的氨基或类似物；R.sup.2代表由以下式表示的基团：（其中R.sup.16代表1到6个碳原子的烷基基团或类似物）或类似物；R.sup.3代表由以下式表示的基团：--O--(CH.sub.2).sub.m --Y（Y代表咪唑基或哌嗪基或类似物，m为1到6）或类似物；R.sup.5代表氢原子、低碳烷基或类似物；A代表由以下式表示的基团：（其中R.sup.6代表氢原子、低碳烷基或类似物），--N.dbd.，或类似物；B代表由以下式表示的基团：（其中R.sup.4代表氢原子或类似物），--N.dbd.，或类似物。
• [EN] SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS<br/>[FR] SULFAMIDES POUR LE TRAITEMENT DES TROUBLES INDUITS PAR L'ENDOTHELINE
  申请人：TEXAS BIOTECHNOLOGY CORPORATION

  公开号：WO1998049162A1

  公开（公告）日：1998-11-05

  (EN) Thienyl-, furyl- and pyrrolyl-sulfonamides, pharmaceutically-acceptable salts of sulfonamides, formulations of salts and the sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides using the formulations and sulfonamides are provided. In particular, formulations of sodium salts of N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides are provided. A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic phase.(FR) L'invention concerne des thiényl-, furyl- et pyrolylsulfamides, des sels pharmaceutiquement acceptables de sulfamides, des formulations de sels et des sulfamides, ainsi que des procédés visant à moduler ou altérer l'activité des peptides appartenant à la famille de l'endothéline au moyen des formulations et des sulfamides en question. En particulier, l'invention concerne des formulations de sels de sodium de N-(isoxazolyl)thiénylsulfamides, N-(isoxazolyl)furylsulfamides, et N-(isoxazolyl)pyrolylsulfamides. L'invention concerne aussi un procédé d'élaboration de sel de métal alcalin à partir d'un sulfamide hydrophobe. Ce procédé consiste à dissoudre un sulfamide libre dans un solvant organique, en présence d'un soluté salin de métal alcalin saturé, et à extraire de la phase organique le sel de sulfamide ainsi formé.

  提供了苯并噻唑基、呋喃基和吡咯基磺酰胺，磺酰胺的药用可接受盐，盐和磺酰胺的制剂，以及使用这些制剂和磺酰胺来调节或改变内皮素家族肽的活性的方法。特别提供了N-(异噁唑基)苯并噻唑磺酰胺、N-(异噁唑基)呋喃磺酰胺和N-(异噁唑基)吡咯磺酰胺的钠盐制剂。提供了一种制备疏水性磺酰胺的碱金属盐的方法。该方法包括在有饱和碱金属盐溶液存在的有机溶剂中溶解自由磺酰胺，并从有机相中回收形成的磺酰胺盐。
• Macrolide antibiotics
  申请人：——

  公开号：US20040077557A1

  公开（公告）日：2004-04-22

  The present invention relates to 11,12 &ggr; lactone ketolides of formula (I) wherein R, R 1 , R 2 , R 3 are as defined herein and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.

  本发明涉及公式（I）中的11,12 &ggr;内酯酮类化合物，其中R、R1、R2、R3如本文所定义的，以及其药学上可接受的盐和溶剂化物，以及它们的制备方法及在人或动物体内治疗或预防全身或局部细菌感染中的应用。
• Macrolide Antibiotics
  申请人：ALIHODZIC Sulejman

  公开号：US20060211636A1

  公开（公告）日：2006-09-21

  The present invention relates to 11,12 γ lactone ketolides of formula (I) wherein R, R 1 , R 2 , R 3 are as defined herein and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.

  本发明涉及式(I)的11,12-γ内酯酮类化合物，其中R、R1、R2、R3如定义所述，以及其药学上可接受的盐和溶剂化物，以及其制备方法和在人或动物体内治疗或预防系统性或局部细菌感染的用途。